| dc.description.abstract | Diabetes mellitus is known as a risk factor for nonalcoholic fatty liver disease (NAFLD) which can progress to nonalcoholic
steatohepatitis (NASH) and eventually lead to hepatocellular carcinoma (HCC) through various stages, including necroinflammatory fibrosis, cirrhosis, and hepatitis. M. oleifera leaves contain flavonoid antioxidants, which inhibit reactive
oxygen species (ROS) and oxidative stress in diabetes mellitus. This study aimed to investigate the potential of M. oleifera
leaf extract at a dosage of 1,000 mg/kgbw to inhibit liver tissue fibrosis in diabetic rats. This study used a true experimental
method with a post-test-only control group design. This study was conducted at the Faculty of Medicine, Universitas
Jember, Jember, Indonesia, from November 2021 to January 2022 on 27 male Wistar rats that were divided into three groups
of nine rats. The rats were induced with streptozotocin and M. oleifera leaf extract at a dosage of 1,000 mg/kgbw. Masson's
trichrome staining and the Meta-analysis of Histological Data in Viral Hepatitis (METAVIR) scoring system were used to
measure liver tissue fibrosis. Data were analyzed using the Kruskal-Wallis and Mann-Whitney tests to examine significant
differences between groups. The results showed a significant difference in the degree of liver tissue fibrosis between the
control and diabetes groups (p=0.00) as well as the diabetes and treatment groups (p=0.003). However, the results did not
show any significant differences between the control and treatment groups (p=0.270). These findings suggested that
administering M. oleifera leaf extract at a dosage of 1,000 mg/kgbw can inhibit liver tissue fibrosis. In conclusion, this
study provides evidence that administering M. oleifera leaf extract can inhibit liver tissue fibrosis in diabetic rats. | en_US |
